Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women Jul 18, 2018 12:59PM
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis Jun 19, 2018 04:02PM
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life Jun 15, 2018 07:00AM
Novartis (NVS) Says FDA Expedited Review of its drug Promacta for first-line SAA May 30, 2018 07:04AM
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA) May 30, 2018 07:00AM


May 17, 2018 09:35AM Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
May 11, 2018 06:35PM Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
Jan 16, 2018 01:21AM Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
Jan 4, 2018 07:15AM Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Jan 3, 2018 07:15AM Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Nov 14, 2012 01:15AM New survey finds women who suffer from migraines want a better understanding of migraine triggers
Sep 4, 2012 01:15AM Higher dose of Novartis drug Exelon® Patch approved by FDA for patients with mild to moderate Alzheimer's disease
Nov 7, 2011 01:15AM Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis